PI Health, a startup co-founded by cancer doctors Jeff Kim and Bobby Ready, built a 30-bed cancer hospital in Hyderabad, India to test its AI-enabled software that streamlines clinical trial workflows and regulatory documentation, significantly accelerating drug approvals. This innovative approach not only reduces trial times and costs but also expands patient access and diversity, aiming to bring new cancer therapies to patients faster worldwide.
PI Health, a startup co-founded by longtime cancer doctors Jeff Kim and Bobby Ready, has taken an innovative approach to accelerate clinical trials by building its own cancer hospital in Hyderabad, India. Recognizing the slow and cumbersome process of patient enrollment and regulatory documentation in clinical trials, the founders aimed to bypass these bottlenecks by creating a state-of-the-art 30-bed cancer hospital. This facility, opened in September 2023, serves as a testing ground for their AI-enabled software designed to streamline clinical trial workflows and regulatory submissions, particularly in overseas and smaller community cancer centers.
Clinical trials are traditionally conducted in top-tier academic medical centers, which limits patient diversity and slows down drug development. PI Health’s software addresses these challenges by consolidating all clinical trial data into a single platform, reducing errors, and automating clinical documentation using artificial intelligence. This technology helps hospitals manage the voluminous paperwork required for regulatory approval more efficiently, thereby expanding the pool of eligible patients and speeding up the trial process. The hospital in Hyderabad has already participated in eight clinical trials, including one that led to the approval of a cancer drug in India in just seven months—less than half the usual time.
The startup’s approach not only accelerates clinical trials but also aims to make cancer therapies available to patients faster and at a lower cost. Only about 8% of cancer patients in the U.S. participate in clinical studies, partly due to the overwhelming paperwork involved. By simplifying and automating these processes, PI Health hopes to increase participation rates, improve understanding of cancer across diverse populations, and reduce the time and expense associated with drug approvals. CEO Jeff Kim emphasizes the urgency of this mission, noting the critical need to get new therapies to patients as quickly as possible.
Founded as an initiative within the cancer drug developer Be Gene, PI Health has raised approximately $40 million and is valued at nearly $100 million. The company has secured contracts worth over $70 million and is involved in nearly 20 clinical studies with five global pharmaceutical companies, including B1 Medicines, which retains a significant stake in the startup. Both Kim and Ready bring extensive experience in oncology and regulatory affairs, having worked at institutions like the FDA, Massachusetts General Hospital, and the National Cancer Institute before launching PI Health.
In summary, PI Health’s bold strategy of building a dedicated cancer hospital in India to test and validate its AI-driven clinical trial software represents a significant innovation in drug development. By streamlining regulatory processes and expanding patient access, the startup aims to reduce the time and cost of clinical trials, ultimately accelerating the delivery of new cancer treatments worldwide. Their success so far demonstrates the potential for technology and strategic infrastructure investments to transform the clinical trial landscape.